We invest in our beliefs; these are mine and why I'm here....

We invest in our beliefs; these are mine and why I'm here.
Godspeed RenovoRx

MOUNTAIN VIEW, CA – February 26, 2025 – RenovoRx, Inc, today announced continuing momentum with the Company’s RenovoCath commercial strategy, with new purchase orders received from several esteemed, high volume National Cancer Institute-designated centers. Additionally, RenovoRx reported that utilization of RenovoCath devices by its initial customers announced this past December has led to repeat purchase orders. Together, these announcements demonstrate that RenovoRx is continuing on the path to initial revenue generation from RenovoCath sales this quarter and that revenues could begin to ramp during the course of 2025.

RenovoRx continues to expand the pipeline of medical institutions that have expressed interest in RenovoCath as a standalone device that addresses high unmet medical needs. RenovoRx expects an average of 5 to 8 annual procedures per patient and pricing similar to other specialty catheters on the market today, ranging from $7,000 to $9,000 per unit. Based on these assumptions and the number of initial target customers being focused on by RenovoRx, the Company believes that the initial total addressable market for RenovoCath has the potential for up to $400 million in peak annual U.S. sales as a standalone device.
“The commercialization momentum with both new and now repeat customers for our proprietary RenovoCath device has accelerated through expanded relationships with high-volume oncology centers across the country. This not only puts us in a position to potentially generate and grow our initial revenues on our own but also puts us in a strengthened negotiation position with potential commercial sales collaborators,” said Shaun Bagai, CEO of RenovoRx. “We are encouraged by the reception for RenovoCath for targeted therapeutic delivery and potential benefits for improved patient outcomes. We believe targeted therapeutic delivery with RenovoCath via our TAMP technology has the potential to transform oncology treatment by enabling precise delivery of agents. We look forward to riding this momentum forward and providing updates as the year progresses.”

For those unaware of IMUGENES association with RenovoRx

NOTE: Check dates of the below.
Los Altos, CA and Sydney, Australia, July 20, 2023 – RenovoRx, Inc., today announced a strategic research collaboration to optimize the delivery of Imugene’s oncolytic virus therapy with RenovoRx’s TAMP (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of difficult-to-access tumors.
“We believe the synergy between RenovoRx’s trans-arterial drug delivery system and our CF33 oncolytic virus platform has the potential to facilitate treatment of difficult-to-access cancers and help patients,” said Leslie Chong, Managing Director & Chief Executive Officer of IMUGENE

“Our collaboration with Imugene is an important milestone for RenovoRx as we expand our pipeline from exclusively treating locally advanced disease to treating metastatic disease with immunotherapy,” said Shaun Bagai, Chief Executive Officer, RenovoRx. “We look forward to combining our proprietary TAMP platform with Imugene’s CF33 oncolytic virus with the goal of optimizing clinical benefits for patients.”

As part of the collaboration, Imugene and RenovoRx will investigate the ability to administer Imugene’s CF33 oncolytic virus technology with RenovoRx’s TAMP therapy platform. The ability to treat difficult-to-access tumors, such as pancreatic and liver cancers, by delivering CF33 trans-arterially may be valuable to cancer patients compared to traditional administration methods where dense fibrous tissue and lack of blood vessels supplying the tumors have been shown to limit therapy uptake.

June 2024“I am thrilled to officially welcome Ryan as our new Senior Vice President, Head of Corporate Strategy and Partnerships,” said Shaun Bagai, CEO of RenovoRx. “Ryan brings extensive corporate strategy and operational experience to this role at RenovoRx. He has already provided important value to our efforts, and we are excited to continue to leverage his expertise as we advance our pivotal Phase III clinical trial, expand development opportunities into additional cancers and explore new commercial business development opportunities with our therapeutic technology.”

“RenovoRx is at an important juncture, and I am excited to step into this role on a permanent basis,” said Mr. Witt. “Building off our collaboration with Imugene and clinical data delivering gemcitabine with our drug-delivery platform, there is incredible potential for RenovoRx’s technology. This is particularly apparent after my experience at Immix and working with over 200 leading Stanford-affiliated companies at StartX. I look forward to pulling from my experience in medical technology and biopharmaceuticals to help RenovoRx realize this opportunity in the form of better outcomes for patients and increased shareholder value.”
IMO